Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Sequana Medical Announces the Completion of Patient Enrolment in POSEIDON, the North American Pivotal alfapump Study

Sequana Medical NV, an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces the completion of patient enrolment in POSEIDON, the North American pivotal study to support regulatory approval of the alfapump system in the U.S. and Canada, for the treatment of recurrent or refractory ascites due to liver cirrhosis.

70 patients have been enrolled in the Pivotal Cohort, with the objective to implant up to 50 patients with the alfapump by the end of Q1 2022 and to evaluate up to 40 patients for the primary endpoint six months post-implantation. Reporting of the primary endpoint is planned for Q4 2022. A further 40 patients were enrolled in the Roll-In Cohort and implanted with the alfapump.

Recommended AI News: Google (Doodle) Honors Prof. Lotfi Zadeh Of UC Berkeley (The Father Of Fuzzy Logic), Who Was Also An Inventor In A Cognitive Explainable-AI (Artificial Intelligence) 3D Image Recognition Software Startup ZAC

Related Posts
1 of 37,908

Ian Crosbie, Chief Executive Officer of Sequana Medical, commented: “Completing the patient enrolment in our POSEIDON study is an important step in bringing the alfapump closer to market approval in the U.S. and Canada. We are grateful to the patients and the clinicians involved in this study. They are allowing us to evaluate the alfapump as a potential treatment option for recurrent or refractory ascites due to liver cirrhosis, which is a growing healthcare problem due to the dramatic rise in non-alcoholic steatohepatitis (NASH). The positive interim results reported in July 2021 demonstrated that the alfapump brings great benefits, including a reduction of more than 90% in the rate of therapeutic paracentesis and clinically important improvements in quality of life. We look forward to reporting the primary endpoint data in Q4 2022, followed by Premarket Approval (PMA) submission to the FDA in mid-2023.

Recommended AI News: mePrism Opens Consumer Data Beta To Give Consumers Data Rights

[To share your insights with us, please write to]

Comments are closed.